Roivant Sciences Ltd.(ROIV)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ROIV Roivant Sciences Ltd.

已收盘 05-11 16:00:00 EDT

28.96

+0.40

+1.40%

盘后28.96

+0.000.00%

18:25 EDT

最高29.51	最低28.60	成交量419.91万
今开28.61	昨收28.56	日振幅3.19%
总市值207.27亿	流通市值135.24亿	总股本7.16亿
成交额1.22亿	换手率0.90%	流通股本4.67亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ROIV","market":"US","secType":"STK","nameCN":"Roivant Sciences Ltd.","latestPrice":28.96,"timestamp":1778529600000,"preClose":28.56,"halted":0,"volume":4199138,"hourTrading":{"tag":"盘后","latestPrice":28.96,"preClose":28.96,"latestTime":"18:25 EDT","volume":509362,"amount":14751163.9328,"timestamp":1778538314792,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.014005602240896434,"floatShares":467000000,"shares":715701137,"eps":-1.173433,"marketStatus":"已收盘","change":0.4,"latestTime":"05-11 16:00:00 EDT","open":28.61,"high":29.51,"low":28.6,"amount":122126054.135938,"amplitude":0.031863,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.173433,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1778572800000},"marketStatusCode":5,"adr":0,"listingDate":1607403600000,"exchange":"NASDAQ","adjPreClose":28.56,"preHourTrading":{"tag":"盘前","latestPrice":28.73,"preClose":28.56,"latestTime":"08:57 EDT","volume":10143,"amount":290228.434524,"timestamp":1778504258893,"change":0.17,"changeRate":0.005952,"amplitude":0.010476},"postHourTrading":{"tag":"盘后","latestPrice":28.96,"preClose":28.96,"latestTime":"18:25 EDT","volume":509362,"amount":14751163.9328,"timestamp":1778538314792,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.00884,"impliedVol":0.7464,"impliedVolPercentile":0.996},"requestUrl":"/m/hq/s/ROIV","defaultTab":"news","newsList":[{"id":"1178419514","title":"Roivant Sciences Ltd. 将于2026年5月20日公布2026财年第四季度及全年业绩并提供业务更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1178419514","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178419514?lang=zh_cn&edition=full","pubTime":"2026-05-12 04:06","pubTimestamp":1778530011,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd. 宣布，公司计划于2026年5月20日（星期三）发布截至2026年3月31日的第四季度及整个2026财年的财务业绩报告。届时，管理层还将提供最新的业务进展与战略更新。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121877200","title":"Roivant Sciences Ltd：牛皮癣3期顶线数据与干燥综合征3期研究启动预计于2026年下半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1121877200","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121877200?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:03","pubTimestamp":1775120599,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.近日披露了其研发管线的重要进展时间表。根据公司规划，针对牛皮癣（Niu）适应症的3期临床试验顶线数据，以及针对干燥综合征（Cs）适应症的3期研究启动，均预计在2026年下半年的日历年内完成。\n这一系列关键节点的设定，标志着公司在自身免疫性疾病领域的研发进入了加速阶段。两项研究的推进，将为Roivant Sciences Ltd.的核心产品线带来重要的临床验证，并可能为未来的商业化奠定基础。市场投资者正密切关注这些里程碑事件，它们对公司估值和长期发展前景具有潜在的重大影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136481161","title":"Roivant拓展Brepocitinib研发计划：启动LPP新2B/3期试验并公布Batoclimax治疗TED的3期研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1136481161","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136481161?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:00","pubTimestamp":1775120417,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd. (ROIV) 宣布扩大其候选药物Brepocitinib的研发计划，将针对扁平苔藓样糠疹（LPP）开展一项新的2B/3期临床试验。同时，公司还公布了另一款药物Batoclimab用于治疗甲状腺眼病（TED）的3期研究结果。\n此次战略扩展彰显了Roivant致力于推进其创新疗法管线，以解决未满足的医疗需求。新启动的LPP试验旨在评估Brepocitinib对这一罕见炎症性瘢痕性脱发疾病的疗效与安全性。而Batoclimab在TED领域的积极3期数据，则为该药物的潜在应用提供了重要支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ROIV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145816069","title":"《新英格兰医学杂志》发布Brepocitinib治疗皮肌炎的三期VALOR试验积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1145816069","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145816069?lang=zh_cn&edition=full","pubTime":"2026-03-29 03:01","pubTimestamp":1774724471,"startTime":"0","endTime":"0","summary":"《新英格兰医学杂志》近日刊发了Brepocitinib在治疗皮肌炎方面的三期VALOR临床试验的积极数据。该研究结果展现了该药物在应对这一自身免疫性疾病方面的显著潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ROIV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616076553","title":"莫德纳解决LNP专利纠纷 将支付22.5亿美元和解金","url":"https://stock-news.laohu8.com/highlight/detail?id=2616076553","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616076553?lang=zh_cn&edition=full","pubTime":"2026-03-04 21:35","pubTimestamp":1772631300,"startTime":"0","endTime":"0","summary":"莫德纳（Moderna，MRNA）同意向Roivant Sciences（ROIV）支付高达22.5亿美元，以解决与其COVID-19疫苗相关的脂质纳米颗粒知识产权索赔，从而避免了原定于下周进行的陪审团审判。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8a24082c651a012a7802d63b3e7455d1","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-04/doc-inhpvtwp3803059.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","ROIV","BK4139","SINA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115450583","title":"Roivant Sciences董事会批准10亿美元股票回购计划，包含2025年6月授权的5亿美元额度","url":"https://stock-news.laohu8.com/highlight/detail?id=1115450583","media":"美股速递","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115450583?lang=zh_cn&edition=full","pubTime":"2026-03-04 05:17","pubTimestamp":1772572633,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd. (ROIV) 宣布，其董事会已正式批准一项总额高达10亿美元的股票回购计划。值得注意的是，此项授权中包含了该公司在2025年6月已批准的5亿美元回购额度。\n这一大规模的回购举措彰显了管理层对公司未来前景的坚定信心，并反映了其致力于通过资本回报为股东创造价值的承诺。通过回购并注销股票，公司有望提升每股收益，从而优化股东权益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABUS","ROIV","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121677386","title":"Roivant Sciences旗下Arbutus正评估于2026年第三季度向股东返还资本","url":"https://stock-news.laohu8.com/highlight/detail?id=1121677386","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121677386?lang=zh_cn&edition=full","pubTime":"2026-03-04 05:17","pubTimestamp":1772572631,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd. (ROIV) 旗下的生物制药公司 Arbutus Biopharma Corporation (ABUS) 目前正在积极评估一项资本返还计划。该计划旨在于2026日历年第三季度向公司股东返还资本。\n","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ABUS","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175985973","title":"Priovant宣布FDA受理并授予Brepocitinib治疗皮肌炎新药申请优先审评资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1175985973","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175985973?lang=zh_cn&edition=full","pubTime":"2026-03-03 20:00","pubTimestamp":1772539222,"startTime":"0","endTime":"0","summary":"生物制药公司Priovant今日宣布，美国食品药品监督管理局（FDA）已正式受理其口服TYK2/JAK1抑制剂Brepocitinib用于治疗成人皮肌炎的新药申请（NDA），并授予该申请优先审评资格。\n此次优先审评标志着Brepocitinib在针对这一罕见、衰弱性自身免疫性疾病的研发进程中迈出了关键一步。若获批，该药物有望为皮肌炎患者提供一种新的重要治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176652125","title":"异动解读 | 旗下药物二期研究显示积极成果，Roivant Sciences盘中大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1176652125","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176652125?lang=zh_cn&edition=full","pubTime":"2026-02-10 04:09","pubTimestamp":1770667748,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.  今日盘中股价大幅上涨5.02%，引起了市场的关注。消息面上，公司旗下Priovant Therapeutics公司宣布，其试验药物brepocitinib在针对皮肤结节病的二期研究中显示出积极成果。研究数据显示，在较高剂量下，患者的皮肤活动性得到显著改善。此外，公司另一家子公司Pulmovant也已完成针对肺动脉高压的实验性药物mosliciguat的二期试验患者招募工作。Priovant表示，计划在与美国食品药品监督管理局协商后，于2026年启动brepocitinib的第三阶段试验。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108390468","title":"异动解读 | 候选药物二期数据积极叠加财报亮眼，Roivant Sciences盘中大涨19.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=1108390468","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108390468?lang=zh_cn&edition=full","pubTime":"2026-02-06 22:58","pubTimestamp":1770389893,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.  今日盘中大涨19.68%，引起了市场的广泛关注。消息面上，公司公布了其候选药物Brepocitinib在治疗皮肤结节病的二期临床试验中取得突破性进展，达到主要疗效终点，患者皮肤病变严重程度获得显著改善。临床数据显示，Brepocitinib作为口服TYK2/JAK1抑制剂，在12周治疗期内表现出优越的安全性与耐受性。财务方面，本季度研发支出集中投向核心管线推进，其中Brepocitinib项目获得重点资源倾斜。这些积极进展共同提振了市场信心，推动了股价的显著上扬。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133289755","title":"Roivant股价盘前飙升15.8%，实验性药物对罕见皮肤病显效及三季度业绩提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1133289755","media":"美股速递","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133289755?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:59","pubTimestamp":1770382753,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd. (ROIV) 股价在盘前交易时段大幅跃升15.8%，此番强劲表现主要受到两大利好因素驱动：其一，公司旗下实验性药物在针对一种罕见皮肤病的临床试验中展现出积极疗效；其二，公司最新公布的第三季度财务业绩超出市场预期。这两项进展共同点燃了投资者的热情，推动股价显著上扬。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185422472","title":"异动解读 | 候选药物二期数据积极叠加财报亮眼，Roivant Sciences盘前大涨9.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=1185422472","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185422472?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:09","pubTimestamp":1770379795,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.  今日盘前股价大涨9.93%，引起了市场的广泛关注。消息面上，公司公布了其候选药物Brepocitinib在治疗皮肤结节病的二期临床试验中取得突破性进展，达到主要疗效终点，患者皮肤病变严重程度获得显著改善。临床数据显示，Brepocitinib作为口服TYK2/JAK1抑制剂，在12周治疗期内表现出优越的安全性与耐受性。财务方面，本季度研发支出集中投向核心管线推进，其中Brepocitinib项目获得重点资源倾斜。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148492221","title":"Roivant公布Brepocitinib治疗皮肤结节病的二期积极数据 同步披露2025财年第三季度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1148492221","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148492221?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:07","pubTimestamp":1770379626,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.  近日宣布其候选药物Brepocitinib在皮肤结节病治疗领域的二期临床试验取得突破性进展。该研究达到主要疗效终点，患者皮肤病变严重程度获得显著改善。与此同时，公司公布了截至2025年12月31日的第三季度财务报告，研发投入与营收增长呈现良性互动态势。临床数据显示，Brepocitinib作为口服TYK2/JAK1抑制剂，在12周治疗期内表现出优越的安全性与耐受性特征。财务方面，本季度研发支出集中投向核心管线推进，其中Brepocitinib项目获得重点资源倾斜。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183978683","title":"Priovant计划与FDA沟通后推进关键项目，三期临床试验拟于2026年启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1183978683","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183978683?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:05","pubTimestamp":1770379512,"startTime":"0","endTime":"0","summary":"生物制药公司Priovant近日宣布，在与美国食品药品监督管理局（FDA）进行深入交流后，公司计划将其核心项目Cs推进至关键阶段。根据最新规划，该项目预计将于2026年正式启动三期临床试验。这一进展标志着该疗法向商业化应用迈出重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190098299","title":"Pulmovant宣布完成Mosliciguat治疗间质性肺病相关肺动脉高压二期Phocus研究患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1190098299","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190098299?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:02","pubTimestamp":1770379352,"startTime":"0","endTime":"0","summary":"生物制药公司Pulmovant今日宣布，其针对间质性肺病相关肺动脉高压（PH-ILD）研发的创新药物Mosliciguat，已顺利完成二期临床试验Phocus研究的全部患者招募工作。该里程碑标志着药物临床开发进入关键数据收集阶段，为后续疗效评估奠定基础。\n本研究旨在评估Mosliciguat在PH-ILD患者中的安全性、耐受性及初步疗效。作为一款选择性可溶性鸟苷酸环化酶激动剂，该药物通过独特作用机制靶向肺动脉高压的病理生理过程。此次完成入组将加速临床试验进程，相关数据结果预计于2024年公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ROIV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136775542","title":"Roivant Sciences将于2026年2月6日公布2025财年第三季度业绩并举行业务更新会","url":"https://stock-news.laohu8.com/highlight/detail?id=1136775542","media":"美股速递","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136775542?lang=zh_cn&edition=full","pubTime":"2026-01-24 05:15","pubTimestamp":1769202912,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd. (ROIV) 计划于2026年2月6日（星期五）发布其截至2025年12月31日的2025财年第三季度财务业绩报告。届时，公司管理层还将同步举行业务更新会议，向投资者和市场详细通报公司的最新运营进展与战略规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ROIV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595726511","title":"Jefferies：Roivant(ROIV.US)2026年迎三大催化剂，目标价看高至 24 美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2595726511","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595726511?lang=zh_cn&edition=full","pubTime":"2025-12-31 14:41","pubTimestamp":1767163270,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Jefferies发布深度研报，聚焦生物技术公司Roivant Sciences的投资前景，通过严谨的财务模型与行业分析，揭示了其未来三大核心催化剂及估值逻辑。研报指出，2026年将成为公司关键转折点，三大催化剂或推动股价显著上行。第三项催化剂为Priovant的brepo药物三期NIU试验数据，其时间节点提前至2026年下半年。基于此，Jefferies给予Roivant“买入”评级，目标价24美元，较最新收盘价21.63美元有10.95%上行空间。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387617.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Jefferies：Roivant(ROIV.US)2026年迎三大催化剂，目标价看高至 24 美元","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104547270","title":"Roivant强调持续的管线进展及公司下一阶段增长的展望——2025投资者日","url":"https://stock-news.laohu8.com/highlight/detail?id=1104547270","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104547270?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:39","pubTimestamp":1765456740,"startTime":"0","endTime":"0","summary":"Roivant强调持续的管线进展及公司下一阶段增长的展望——2025投资者日","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516663104","title":"Roivant Sciences Ltd.盘中异动 下午盘股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516663104","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516663104?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:07","pubTimestamp":1741032469,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时07分，Roivant Sciences Ltd.股票出现波动，股价急速跳水5.03%。截至发稿，该股报10.20美元/股，成交量383.384万股，换手率0.54%，振幅5.77%。Roivant Sciences Ltd.股票所在的生物技术行业中，整体涨幅为0.17%。Roivant Sciences Ltd.公司简介：Roivant Sciences Ltd是一家处于商业阶段的生物制药公司，致力于改善向患者提供医疗保健。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304040749a25d9d08&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304040749a25d9d08&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ROIV","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117070208","title":"异动解读 | 生物技术股Roivant Sciences Ltd.(ROIV)盘中大涨5.51% 市场看好公司前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1117070208","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117070208?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:52","pubTimestamp":1739199156,"startTime":"0","endTime":"0","summary":"生物技术公司Roivant Sciences Ltd.今日盘中股价大涨5.51%,引发市场关注。这或与以下几个原因有关:. 首先,公司最新财报数据获得市场认可。公司继续积极推进旗下重磅药物如VTAMA、Batoclimab等的研发。其次,券商机构对ROIV股票给予了较高评级。这表明分析师看好ROIV的长期增长前景。最后,生物技术整个行业今日整体呈现上涨趋势,带动了ROIV作为龙头股的表现。如Ocean Biomedical、Biodexa等个股涨幅较大,再次证明该行业的资金持续保持流入态势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://roivant.com;investor.roivant.com","stockEarnings":[{"period":"1week","weight":0.0262},{"period":"1month","weight":0.0138},{"period":"3month","weight":0.1061},{"period":"6month","weight":0.3851},{"period":"1year","weight":1.5893},{"period":"ytd","weight":0.3161}],"compareEarnings":[{"period":"1week","weight":0.0235},{"period":"1month","weight":0.0911},{"period":"3month","weight":0.0681},{"period":"6month","weight":0.0993},{"period":"1year","weight":0.3054},{"period":"ytd","weight":0.0817}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Roivant Sciences Ltd.是一家于2020年7月6日成立的注册于百慕大群岛的公司。Roivant的使命是通过将每一个低效率都视为机会来改善为患者提供的医疗保健服务。Roivant通过以创造性的方式构建技术和培养人才，利用Roivant平台推出“Vants”——灵活且专注的生物制药和健康技术公司，从而更快地开发变革性药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.071559},{"month":2,"riseRate":0.333333,"avgChangeRate":0.052607},{"month":3,"riseRate":0,"avgChangeRate":-0.087601},{"month":4,"riseRate":0.833333,"avgChangeRate":0.021573},{"month":5,"riseRate":0.5,"avgChangeRate":0.027115},{"month":6,"riseRate":0.8,"avgChangeRate":0.015077},{"month":7,"riseRate":0.8,"avgChangeRate":0.040575},{"month":8,"riseRate":0.6,"avgChangeRate":0.00833},{"month":9,"riseRate":0.4,"avgChangeRate":0.013102},{"month":10,"riseRate":0.6,"avgChangeRate":0.101456},{"month":11,"riseRate":0.8,"avgChangeRate":0.02515},{"month":12,"riseRate":0.8,"avgChangeRate":0.23185}],"exchange":"NASDAQ","name":"Roivant Sciences Ltd.","nameEN":"Roivant Sciences Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roivant Sciences Ltd.(ROIV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Roivant Sciences Ltd.(ROIV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Roivant Sciences Ltd.,ROIV,Roivant Sciences Ltd.股票,Roivant Sciences Ltd.股票老虎,Roivant Sciences Ltd.股票老虎国际,Roivant Sciences Ltd.行情,Roivant Sciences Ltd.股票行情,Roivant Sciences Ltd.股价,Roivant Sciences Ltd.股市,Roivant Sciences Ltd.股票价格,Roivant Sciences Ltd.股票交易,Roivant Sciences Ltd.股票购买,Roivant Sciences Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roivant Sciences Ltd.(ROIV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Roivant Sciences Ltd.(ROIV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}